The 120% FILSPARI growth and 1,932 PSFs confirm strong commercial execution in IgAN and early FSGS launch momentum. The $113.1M IPRD charge for civorebrutinib is a one-time non-cash item; watch for the IND submission by year-end and Phase 3 HARMONY data in 2H 2027 as the next catalysts. The CEO transition is orderly and pre-announced.
Drugs in focus
TVTX drug pipeline →pegtibatinase
● Neutral Named in this 8-K- Impact
- Phase
- Phase 3
- Time to market
- If the Phase 3 HARMONY study succeeds, a regulatory filing could follow the topline data (expected 2H 2027), with potential FDA approval potentially 12-18 months later, suggesting a possible 2029-2030 launch at the earliest.
- Next catalyst
- None dated
What to watchThe next major catalyst is the Phase 3 HARMONY topline data readout in 2H 2027. Positive data would position pegtibatinase as the first disease-modifying therapy for classical HCU and likely drive significant upside. Negative data or further manufacturing delays would be substantially damaging, though FILSPARI revenues provide a partial buffer.
How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+5- T+0 · Nov 3 $49.41entry
- T+1 · 13d ago +6.09%α +4.44% · $52.42
- T+5 · 7d ago +5.22%α +5.81% · $51.99
- T+9 · todayOpen
- T+20 · in 15d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Travere Therapeutics reported Q3 2026 FILSPARI net product sales of $200.2M, up 120% YoY, and total revenue of $224.6M, well above the $195.3M consensus. However, GAAP net loss was $52.3M ($0.55/share) versus net income of $25.7M a year ago, driven by a $113.1M IPRD charge for the civorebrutinib license and higher R&D and SG&A spending. The company ended the quarter with $471.8M in cash and securities.
Key Financial Metrics
Key Facts
- FILSPARI net product sales of $200.2M in Q3 2026, up 120% year-over-year from $90.9M
- Total revenue of $224.6M, up from $164.9M in Q3 2025
- 1,932 new patient start forms (PSFs) received during Q3 2026
- GAAP net loss of $52.3M ($0.55 per share) vs net income of $25.7M ($0.29 per share) in Q3 2025
- Non-GAAP net loss of $29.6M ($0.31 per share) vs non-GAAP net income of $52.8M ($0.59 per share) in Q3 2025
- Recognized $113.1M in-process R&D expense for civorebrutinib licensing deal with Everest Medicines
- Cash, cash equivalents and marketable securities of $471.8M as of September 30, 2026
- Convertible debt increased to $603.5M from $311.7M at year-end 2025
- Phase 3 HARMONY Study of pegtibatinase enrollment progressing, topline data expected 2H 2027
- CEO transition announced: Bradley Campbell to succeed Eric Dube effective December 1, 2026
Financial Impact
FILSPARI sales grew 120% YoY to $200.2M, total revenue beat consensus by ~$29M; GAAP net loss widened to $52.3M due to $113.1M IPRD charge
Segment Breakdown
| Segment | Revenue | Growth |
|---|---|---|
| FILSPARI | $200.2M | +120.2% |
| Tiopronin products | $20.0M | -10.1% |
Risk Factors
- GAAP net loss widened sharply due to $113.1M IPRD charge and higher operating expenses
- Convertible debt nearly doubled to $603.5M, increasing leverage
- Phase 3 HARMONY Study results not expected until 2H 2027, a binary event
- CEO transition introduces execution risk, though orderly
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001438533-26-000074 |
| Document: tvtx-20261102.htm | 0001438533-26-000074 |
| Document: 0001438533-26-000074-index-headers.html | 0001438533-26-000074 |
| Document: 0001438533-26-000074-index.html | 0001438533-26-000074 |
| Document: 0001438533-26-000074.txt | 0001438533-26-000074 |
| 8-K Data (Synthetic) | 0001438533-26-000074 |
Track record
21 reports on TVTX
7 of 9 bullish or bearish reports moved the stock their way by T+5. Best: +56.24% at T+60 after the Jun 2, 2026 report. 9 of 9 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $50.30 Now $49.70 −1.19% settles Nov 23
- Nov 5, 202611d ago SC 13G/A Neutral 2/10 Entry $48.87 to $51.56 Now $49.70 +1.70% ▲ +5.50% +2.21% vs SPY
- Nov 3, 202613d ago Institutional Cluster Bullish 4/10 Entry $49.41 to $51.99 Now $49.70 +0.59% ▲ +5.22% +5.81% vs SPY
- Nov 2, 202614d ago 8-K Bullish 6/10 Viewing Entry $49.41 to $51.99 Now $49.70 +0.59% ▲ +5.22% +5.81% vs SPY
- Sep 17, 20268w ago Insider Cluster Bearish 4/10 Entry $62.76 to $59.44 Now $49.70 +20.81% ▲ +5.29% +6.56% vs SPY
- Jul 9, 202618w ago 8-K Neutral 2/10 Entry $56.59 to $55.28 Now $49.70 −12.18% ▼ −2.31% −1.75% vs SPY
- Jun 16, 202621w ago Insider Cluster Neutral 2/10 Entry $54.14 to $57.69 Now $49.70 −8.20% ▲ +6.56% +7.60% vs SPY
- Jun 16, 202621w ago 8-K Neutral 2/10 Entry $54.14 to $57.69 Now $49.70 −8.20% ▲ +6.56% +7.60% vs SPY
- Jun 12, 202622w ago 144 Neutral 2/10 Entry $52.04 to $55.15 Now $49.70 −4.50% ▲ +5.98% +5.30% vs SPY
- Jun 2, 202623w ago 8-K Bullish 6/10 Entry $42.96 to $48.57 Now $49.70 +15.69% ▲ +13.06% +16.02% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers